PropertyValue
?:abstract
  • Aim: Novel biomarkers that are able to accurately monitor tuberculosis (TB) treatment effectiveness are needed to adjust therapy and identify a need for a regimen change. Materials & methods: In our study, conducted on a cohort comprising 100 pulmonary TB patients, we analyzed the role of plasma cytokines and toll-like receptors expression as biomarkers of treatment response. Results: Changes in toll-interacting protein (TOLLIP) and lymphocyte antigen 96 (LY96) gene expression as well as nine cytokine levels over the first 2 months were significantly associated with successful treatment outcome. Successful treatment was associated with higher serum concentration of toll-like receptor-2. Conclusion: Our results suggest that differential expression of specific effector molecules and dynamics of selected cytokines may help to identify those responding to TB treatment early.
is ?:annotates of
?:creator
?:doi
  • 10.2217/bmm-2020-0246
?:doi
?:journal
  • Biomarkers_in_medicine
?:license
  • unk
?:pmid
?:pmid
  • 33140661
?:publication_isRelatedTo_Disease
?:source
  • Medline
?:title
  • Biomarkers of treatment success in fully sensitive pulmonary tuberculosis patients: a multicenter longitudinal study.
?:type
?:year
  • 2020-11-03

Metadata

Anon_0  
expand all